1μg (R: reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | CD27 Ligand; CD27-L; CD27L; CD27LG; CD70 molecule; CD70; Ki-24 antigen; surface antigen CD70; TNFSF7; TNFSF7CD70 antigen; tumor necrosis factor (ligand) superfamily, member 7; Tumor necrosis factor ligand superfamily member 7 |
Accession | P32970 |
Amino Acid Sequence | Gly54-Pro193 with Human IgG1 Fc & His Tag at C-Terminus |
Expression System | HEK293 |
Molecular Weight | 72-95kDa (Reducing) |
Purity | > 95% by SDS-PAGE & SEC-HPLC |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag, Human IgG1 Fc |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4, 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Background
Cluster of Differentiation 70 (CD70), also known as CD27 ligand (CD27L/CD27LG) or TNFSF7, is a type II transmembrane glycoprotein belonging to the Tumor Necrosis Factor (TNF) superfamily. CD70 is a surface antigen expressed on activated T- and B-lymphocytes and mature dendritic cells. The interaction of CD70 with its receptor CD27 leads to the priming, effector functions, differentiation, and memory formation of T-cells. Consequently, CD70 is involved in biological processes including T-cell activation, proliferation of costimulated T-cells, and the generation of cytolytic T-cells. On T-cells, CD70 provides costimulatory signals necessary for T cell proliferation, clonal expansion, and the promotion of effector T cell formation. In mice, CD70 on B-cells has been shown to inhibit the terminal differentiation of activated B cells into plasma cells and to enhance commitment to memory B cell responses. Additionally, CD70 induces proliferation and IFNγ production in NK cells.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of CD27 Ligand/CD70 Fc&His Tag Trimer design Protein, Human is greater than 95% as determined by SEC-HPLC.
ELISA
Immobilized CD27/TNFRSF7 His Tag Protein, Human (Cat. No. UA010124) at 2.0μg/mL (100μL/well) can bind CD27 Ligand/CD70 Fc&His Tag Trimer design Protein, Human (Cat. No. UA011141) with EC50 of 6.35-9.46 ng/ML. The Competitor A shows EC50 of 6.55-8.36 ng/ML.

Serial dilutions of V6 Anti-Human CD70 (Cusatuzumab) were added into CD27 Ligand / CD70 Fc Tag,His tag, Trimer design Human (Cat. No. UA011141): Biotinylated CD27/TNFRSF7 His Tag Protein, Human binding reactions. The half maximal inhibitory concentration (IC50) is 0.44 μg/mL.
